TLDR Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
The document presents the results of two Phase 3 trials (BRAVE-AA1 and BRAVE-AA2) on the long-term efficacy and safety of baricitinib, a drug used for severe alopecia areata (AA). The study found that continuous monotherapy with baricitinib over 104 weeks maintained efficacy, with 90.7% of patients treated with 4mg and 89.2% of patients treated with 2mg maintaining clinical response at Week 104. The study also found that long-term treatment is necessary to observe maximum benefit. The most common treatment-emergent adverse events (TEAEs) were COVID-19, upper respiratory tract infection, headache, nasopharyngitis, acne, urinary tract infection, and creatine phosphokinase increase. The study concluded that long-term therapy may be necessary for disease control in severe AA, and continuous baricitinib treatment over 104 weeks showed cumulative benefit on hair regrowth and improved quality of life. There were few discontinuations and no new safety signals over the long-term observation period.
20 citations,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
[object Object] 
25 citations,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
148 citations,
March 2022 in “The New England Journal of Medicine” Baricitinib was effective in treating alopecia areata in two major trials.
30 citations,
September 2020 in “Journal of Patient-Reported Outcomes” Alopecia Areata (AA) causes significant emotional distress, including feelings of embarrassment, depression, and anxiety, and impacts social interactions and daily activities.
130 citations,
February 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.
63 citations,
July 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
[object Object] 
95 citations,
July 2016 in “Journal of The American Academy of Dermatology” People with alopecia areata, a skin disease, generally have a poor quality of life, especially if more of their scalp is affected.
October 2023 in “Acta dermato-venereologica (Print)” People with severe hair loss have lower zinc levels in their blood.
[object Object]
